Advertisement
U.S. Markets closed
  • S&P 500

    5,160.64
    -49.27 (-0.95%)
     
  • Dow 30

    38,461.51
    -422.16 (-1.09%)
     
  • Nasdaq

    16,170.36
    -136.28 (-0.84%)
     
  • Russell 2000

    2,028.39
    -52.41 (-2.52%)
     
  • Crude Oil

    86.25
    +1.02 (+1.20%)
     
  • Gold

    2,352.40
    -10.00 (-0.42%)
     
  • Silver

    28.06
    +0.07 (+0.25%)
     
  • EUR/USD

    1.0747
    -0.0112 (-1.0317%)
     
  • 10-Yr Bond

    4.5600
    +0.1940 (+4.44%)
     
  • Vix

    15.80
    +0.82 (+5.47%)
     
  • GBP/USD

    1.2541
    -0.0136 (-1.0735%)
     
  • USD/JPY

    153.0600
    +1.3050 (+0.8600%)
     
  • BTC-USD

    69,812.38
    +715.22 (+1.04%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,961.21
    +26.42 (+0.33%)
     
  • Nikkei 225

    39,581.81
    -191.32 (-0.48%)
     

Broker Revenue Forecasts For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher

Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have sharply increased their revenue numbers, with a view that Bicycle Therapeutics will make substantially more sales than they'd previously expected. The market seems to be pricing in some improvement in the business too, with the stock up 7.0% over the past week, closing at US$21.77. Could this big upgrade push the stock even higher?

Following the upgrade, the most recent consensus for Bicycle Therapeutics from its 14 analysts is for revenues of US$20m in 2023 which, if met, would be a huge 41% increase on its sales over the past 12 months. Per-share losses are expected to explode, reaching US$4.60 per share. However, before this estimates update, the consensus had been expecting revenues of US$16m and US$4.63 per share in losses. So there's been quite a change-up of views after the recent consensus updates, withthe analysts noticeably increasing their revenue forecasts while also expecting losses per share to hold steady.

See our latest analysis for Bicycle Therapeutics

earnings-and-revenue-growth
earnings-and-revenue-growth

There were no major changes to the US$52.79 consensus price target despite the higher revenue estimates, with the analysts seeming to believe that ongoing losses have a larger impact on the valuation than growing sales. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Bicycle Therapeutics analyst has a price target of US$72.00 per share, while the most pessimistic values it at US$33.00. This is a fairly broad spread of estimates, suggesting that the analysts are forecasting a wide range of possible outcomes for the business.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Bicycle Therapeutics' growth to accelerate, with the forecast 41% annualised growth to the end of 2023 ranking favourably alongside historical growth of 18% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 13% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Bicycle Therapeutics to grow faster than the wider industry.

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Bicycle Therapeutics is moving incrementally towards profitability. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Bicycle Therapeutics.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Bicycle Therapeutics analysts - going out to 2025, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

Advertisement